07.10.2015 • NewsDede WillamsCovestroEngineering Plastics

Covestro Share Launch Successful

German engineering plastics producer Covestro and its parent company Bayer successfully placed 62.5 million shares of the former Bayer MaterialScience in the Prime Standard of the Frankfurt Stock Exchange on Oct. 6.

The issue was three times oversubscribed, and stock market watchers said the paper was picked up by investors based in Germany and in English-speaking countries, including the US.

After starting the first day of trading at an issue price of €24, the listing price quickly rose to finally settle above €26 – a gain of more than 12%. Toward the end of the book-building process, the proposed range had been taken back from €26.50-35.50 per share to €21.50-34.50, which analysts said boosted its prospects.

Although originally planning the launch proceeds at €2.5 billion, the Leverkusen giant, which is repositioning itself as a pure life science player, dropped its target by €1 billion to keep the new standalone company’s net indebtedness at €4 billion.

The Covestro shares are also being offered to investors in Luxembourg in addition to Frankfurt. Following the successful placement, Bayer’s stake in its former sub-group has sunk to 69%, and the German group is aiming for future gradual reductions.

Virtual Event

Digitalization in the Chemical Industry
CHEManager Spotlight

Digitalization in the Chemical Industry

Save the Date: October 22, 2025
The event will be promoted to a combined audience of over 100,000 professionals across Europe through the CHEManager and CITplus networks.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

most read

Photo
13.03.2025 • News

Roche and Zealand Pharma Collaborate on Weight Management Drug

Swiss pharma heavyweight Roche announced has entered into an exclusive collaboration and licensing agreement with Denmark’s Zealand Pharma. Under the terms of this agreement, the two companies will collaborate to co-develop and co-commercialize petrelintide, Zealand Pharma’s amylin analog as a standalone therapy as well as a fixed-dose combination with Roche’s lead incretin asset CT-388.

Photo
19.03.2025 • News

Arkema Launches Acrylic Acid Purification Project

Arkema has announced the launch of its Carat Project at its Carling site in France. This initiative aims to enhance the capabilities and sustainability of the facility, which specializes in producing acrylic monomers and superabsorbent polymers.